Pharmacotyping of hypokalaemic salt-losing tubular disorders.

UNLABELLED Long standing confusion exists in the terminology of hypokalaemic salt-losing tubulopathies (SLTs). SLTs are autosomal recessively transmitted and characterized by normotensive secondary hyperreninism/hyperaldosteronism with hypokalaemic metabolic alkalosis. Historically, four phenotypical variants have been described: (1) the (classic) Bartter syndrome (cBS), (2) the hypomagnesaemic hypocalciuric Gitelman syndrome (GS), (3) the hypercalciuric hyperprostaglandin-E-syndrome (HPS) or antenatal Bartter syndrome (aBS) and (4) the hyperprostaglandin-E-syndrome with sensorineural deafness (HPS + SND). The latter two syndromes are the most severe variants with antenatal manifestation with polyhydramnios and life-threatening course of salt- and water-loss. Defects in five renal membrane proteins involved in electrolyte reabsorption have been identified: In HPS-patients mutations in (1) either the furosemide-sensitive sodium-potassium-chloride cotransporter NKCC2, or (2) in the potassium channel ROMK have been identified, and (3) HPS + SND is caused by mutations in the beta-subunit of the chloride channels ClC-Kb and -Ka (named barttin), all mimicking the major pharmacological effects of furosemide with minor potassium-wasting in ROMK-patients as seen in patients treated with simultaneous furosemide and amiloride, and minor calcium-wasting in Barttin-patients resembling the combination of furosemide and thiazides. (4) cBS is caused by mutations in the chloride channel ClC-Kb with similar clinical characteristics as seen under combination of thiazides and furosemide, (5) GS is caused by mutations in the thiazide-sensitive sodium-chloride cotransporter NCCT resembling the effect of long-term thiazide administration. CONCLUSION The combination of pharmacology and genetics suggests a new terminology for the above described SLTs: Furosemide-like-SLT for HPS caused by NKCC2-mutations, furosemide/amiloride-like-SLT for HPS caused by ROMK-mutations, furosemide/thiazide-like-SLT for HPS + SND, thiazide/furosemide-like-SLT for cBS, and thiazide-like-SLT for GS.

[1]  P. Komlósi,et al.  Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. , 2003, The Journal of clinical investigation.

[2]  O. Birk,et al.  Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome. , 2003, The Journal of pediatrics.

[3]  O. Ateş,et al.  Induction of fetal diuresis with intraamniotic furosemide increases the clearance of intraamniotic substances: An alternative therapy aimed at reducing intraamniotic meconium concentration. , 2002, Journal of pediatric surgery.

[4]  H. Seyberth,et al.  Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. , 2002, Kidney international.

[5]  M. Konrad,et al.  Barttin increases surface expression and changes current properties of ClC-K channels , 2002, Pflügers Archiv.

[6]  B. Tönshoff,et al.  Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. , 2002, The American journal of medicine.

[7]  F. Hildebrandt,et al.  Barttin is a Cl- channel β-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion , 2001, Nature.

[8]  K. Lackner,et al.  Low sodium and furosemide‐induced stimulation of the renin system in man is mediated by cyclooxygenase 2 , 2001, Clinical pharmacology and therapeutics.

[9]  H. Omran,et al.  Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure , 2001, Nature Genetics.

[10]  M. Konrad,et al.  Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. , 2001, Pediatrics.

[11]  R. Lifton,et al.  Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. , 2001, Kidney international.

[12]  M. Konrad,et al.  Mutations in the Chloride Channel Gene, CLCNKB, Leading to a Mixed Bartter-Gitelman Phenotype , 2000, Pediatric Research.

[13]  C. Antignac,et al.  Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. , 2000, Journal of the American Society of Nephrology : JASN.

[14]  G. Casari,et al.  Gitelman Disease Associated with Growth Hormone Deficiency, Disturbances in Vasopressin Secretion and Empty Sella: A New Hereditary Renal Tubular-Pituitary Syndrome? , 1999, Pediatric Research.

[15]  H. Devlieger,et al.  Neonatal Bartter syndrome: spontaneous resolution of all signs and symptoms , 1998, Pediatric Nephrology.

[16]  V. Sheffield,et al.  Linkage of infantile Bartter syndrome with sensorineural deafness to chromosome 1p. , 1998, American journal of human genetics.

[17]  T. Mansfield,et al.  Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III , 1997, Nature Genetics.

[18]  A. Karschin,et al.  Mutations in the ROMK gene in antenatal Bartter syndrome are associated with impaired K+ channel function. , 1997, Biochemical and biophysical research communications.

[19]  R. Lifton,et al.  Genetic heterogeneity of Barter's syndrome revealed by mutations in the K+ channel, ROMK , 1996, Nature Genetics.

[20]  H. Seyberth,et al.  Impaired response to furosemide in hyperprostaglandin E syndrome: evidence for a tubular defect in the loop of Henle. , 1996, The Journal of pediatrics.

[21]  R. Lifton,et al.  Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na–K–2CI cotransporter NKCC2 , 1996, Nature Genetics.

[22]  R. Carmi,et al.  Infantile variant of Bartter syndrome and sensorineural deafness: a new autosomal recessive disorder. , 1995, American journal of medical genetics.

[23]  K. Schärer,et al.  Pre-pubertal growth in the hyperprostaglandin E syndrome , 1995, Pediatric Nephrology.

[24]  G. Colussi,et al.  Distal nephron function in Bartter's syndrome: abnormal conductance to chloride in the cortical collecting tubule? , 1992, American Journal of Nephrology.

[25]  H. Endou,et al.  Furosemide directly stimulates prostaglandin E2 production in the thick ascending limb of Henle's loop. , 1989, The Journal of pharmacology and experimental therapeutics.

[26]  W. Rascher,et al.  Role of prostaglandins in hyperprostaglandin E syndrome and in selected renal tubular disorders , 1987, Pediatric Nephrology.

[27]  K. Schärer,et al.  Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome. , 1985, The Journal of pediatrics.

[28]  A. Ohlsson,et al.  A Variant of Bartter's Syndrome , 1984, Acta paediatrica Scandinavica.

[29]  A. Amery,et al.  Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. , 1976, Kidney international.

[30]  B. Scoggins,et al.  POTASSIUM‐LOSING NEPHROPATHY OF CHILDHOOD , 1971, The Medical journal of Australia.

[31]  J. Gill,et al.  Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. , 1962, The American journal of medicine.

[32]  R. Szargel,et al.  A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. , 2003, Kidney international.

[33]  A. Ziegler,et al.  Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: evidence for genetic heterogeneity. International Collaborative Study Group for Bartter-like Syndromes. , 1997, Human molecular genetics.

[34]  R. Lifton,et al.  Gitelman's variant of Barter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na–Cl cotransporter , 1996, Nature Genetics.

[35]  R. Hené,et al.  Discrepancy between lithium and free water clearance in patients with Bartter's syndrome. , 1994, Nephron.

[36]  T. Kelly,et al.  Hemodynamic and fluid responses to furosemide infusion in the ovine fetus. , 1993, American journal of obstetrics and gynecology.

[37]  E. Girardin,et al.  Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes. , 1992, The Journal of pediatrics.

[38]  R. Sutton,et al.  Bartter's syndrome: evidence suggesting a distal tubular defect in a hypocalciuric variant of the syndrome. , 1992, Mineral and electrolyte metabolism.

[39]  R. Hené,et al.  Variant of Bartter's syndrome with a distal tubular rather than loop of henle defect. , 1989, Nephron.

[40]  J. Veldhuis,et al.  The clinical entity of pseudo-Bartter's syndrome. , 1980, Advances in prostaglandin and thromboxane research.